Effect of pharmacist intervention on glycemic control in diabetes

Collins, Courtney; Limone, Brendan; Scholle, Jennifer M; Coleman, Craig I.

doi:10.1016/j.diabres.2010.09.023

Cited by 81 publications

(83 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The studies with beneficial results on those indexes usually adopt a longer PTF than employed in our study, and that may be a determinant for such purpose (Lyra Junior et al 2011;Al Mazroui et al, 2009;Chung et al, 2014;Collins et al, 2011).…”

Section: Discussionmentioning

confidence: 99%

Cardiovascular risk rate in hypertensive patients attended in primary health care units: the influence of pharmaceutical care

Firmino

Vasconcelos²,

Ferreira³

et al. 2015

Braz. J. Pharm. Sci.

View full text Add to dashboard Cite

Cardiovascular complications are relevant due to their frequency and severity on the hypertension scenario. Studies refer Pharmaceutical Care (PC) as capable of decreasing cardiovascular risk rate (%CVR) on hypertensive patients. This study aimed to investigate, through a randomized clinical assay, the influence of PC service on the %CVR of hypertensive patients assisted in a health primary care unit from Fortaleza-Ceará. Two study groups were formed: i. Intervention Group (IG), which received orientation about taking medicines, actions aiming to prevent/solve medicine interactions and adverse effects and non-pharmacological interventions for 9 months and, ii. Control Group (CG), which received traditional assistance of the unit and was monitored during the same period. It was observed a statistically significant reduction on %CVR (10.76 to 7.86; p=0.04) and systolic blood pressure levels (SBP) (137.69 to 131.54; p<0.01) in the IG, while, in the CG, there was no significant alteration. 151 Drug Related Problem (DRP) were identified and it was realized 124 pharmaceutical interventions, with 89.2% of them resulting on solution/prevention of the problem. Our findings indicated that the inclusion of the PC service in the hypertensive health assistance was more effective at the %CVR and the SBP reduction in comparison to the traditional assistance offered.Uniterms: Pharmaceutical care. Cardiovascular risk. Hypertension.As complicações cardiovasculares apresentam relevância devido à sua freqüência e gravidade no contexto da hipertensão. Estudos referem que a prestação do Cuidado Farmacêutico (CF) é capaz de reduzir a taxa de risco cardiovascular (%RCV) em hipertensos. Esse trabalho objetivou investigar, com um ensaio clínico randomizado, a influência da prestação do CF na %RCV em hipertensos atendidos em uma unidade de atenção primária à saúde de Fortaleza-Ceará. Formarm-se dois grupos de estudo: i. Grupo Intervenção (GI), que recebeu orientações sobre tomada dos medicamentos, ações visando prevenir/ resolver interações medicamentosas e reações adversas e intervenções não-farmacológicas por 9 meses e ii. Grupo Controle (GC), que recebeu assistência tradicional da unidade e foi monitorado durante o mesmo período. Observou-se redução estatisticamente significativa nas %RCV (10,76 to 7,86; p=0,04) e nos níveis de pressão arterial sistólica (PAS) (137,69 to 131,54; p<0,01) no GI, enquanto no GC, não houve alteração significativa. Identificaram-se 151 Problemas Relacionados com Medicamentos (PRM) e foram realizadas 124 intervenções farmacêuticas, das quais, 89,2% resultaram em solução/prevenção dos problemas. Nossos achados indicaram que a inclusão do serviço de CF na assistência ao paciente hipertenso foi mais eficaz na redução da %RCV e níveis de PAS em comparação à assistência tradicional.

show abstract

Section: Discussionmentioning

confidence: 99%

Cardiovascular risk rate in hypertensive patients attended in primary health care units: the influence of pharmaceutical care

Firmino

Vasconcelos²,

Ferreira³

et al. 2015

Braz. J. Pharm. Sci.

View full text Add to dashboard Cite

show abstract

“…As part of a health care team, pharmacists, with a more extensive patient contact, can contribute to patient follow-up by providing diabetes education and self-care incentives. Studies have shown significant improvements in HbA1c values, fasting glucose levels, and compliance indicators, when pharmacists are included in the health care team, thereby improving the subjective perception of QoL (Correr, Otuki, 2013;Jennings, Marx, 2012;Collins et al, 2011;Armor et al, 2010;Campbell, 2002).…”

Section: Discussionmentioning

confidence: 99%

Quality of life perception of type 1 diabetic patients treated with insulin analogs and receiving medication review with follow-up in a public health care service from Ponta Grossa-PR, Brazil

Garabeli

Daher

Wiens

et al. 2016

Braz. J. Pharm. Sci.

View full text Add to dashboard Cite

Glycemic control in patients with diabetes mellitus type 1 (DM1) reduces the risk of complications but requires a rigorous health care routine. Thus, diabetes education is central to increasing treatment compliance and self-care practices. This study aimed to evaluate the quality of life (QoL) and glycemic control of DM1 patients being treated with insulin analogs and receiving medication review with followup. This was a transversal study that included 110 patients registered at the 3 rd Health Regional of Ponta Grossa-PR, aged ≥ 18 years, and receiving pharmaceutical care for at least 1 year. The Diabetes Quality of Life Measure (DQOL)-Brazil was used to evaluate QoL. The data were statistically analyzed using SPSS version 17.0 with 95% confidence levels. Of the 110 patients, 58.2% were women. The average age was 33.7 years (±10.5), and the average glycated hemoglobin (HbA1c) value was 8% (±1.4). The mean total DQOL-Brazil score was 2.11 (95% confidence interval, 2.02 -2.21). All DQOL-Brazil scores were lower in patients with HbA1c ≤ 8%, indicating a better QoL. Good glycemic control, thus, appears to have a positive influence on the QoL, and pharmaceutical interventions are able to contribute to the achievement of therapeutic targets.Uniterms: Diabetes mellitus type 1/treatment. Diabetes mellitus type 1/treatment/quality of life. Pharmaceutical care. Insulin analogs. Pharmacotherapy follow-up. INTRODUCTIONDiabetes mellitus (DM) is a group of metabolic d i s o r d e r s p r i m a r i l y c h a r a c t e r i z e d b y c h r o n i c hyperglycemia. High glycemic levels are associated with micro-and macrovascular complications leading to damage to, and failure of organs such as the eyes (retinopathy), kidneys (nephropathy), nerves (neuropathy), heart, and blood vessels (ADA, 2016; Braga de Souza et al., 2015;Gross et al., 2002).According to the Diabetes Control and Complications Trial (DCCT), the risk of developing chronic complications is higher in patients with chronically high glycated hemoglobin (HbA1c) levels, and the risk gradually increases with HbA1c levels greater than 7% (Pimazoni Netto et al., 2009). The American Diabetes Association (ADA) defines an HbA1c value < 7% as the acceptable limit for diabetes control. With good glycemic control, patients can be symptom-free, and prevent acute and chronic complications (ADA, 2016;UKPDS, 1999;DCCT, 1988).DM is a chronic condition that requires daily self-care throughout life and has a negative impact on the subjective perception of the quality of life (QoL). However, daily treatment is fundamental to DM control and decreases the risk of complications (Debaty et al., 2008;Wood-Dauphinee, 1999). DM1 therapy includes intensive care demands such as daily blood glucose monitoring, multiple insulin injections, and specific dietary and physical activity recommendations (ADA, 2016). Not understanding all these recommendations and a lack of compliance to treatment leads to a poor glycemic control that can cause severe hyper-or hypoglycemia episodes and chronic complicat...

show abstract

“…Os resultados dmostraram associações estatisticamente e clinicamente significativas entre a intervenção do farmacêutico e a melhora no controle glicêmico (48).…”

Section: Contextualização Do Agravo à Saúde: Diabetes Tipounclassified

Benefícios Decorrentes De Prática Do Cuidado Farmacêutico Em Hipertensão E Diabetes Tipo 2 Para Sua Efetivação Em Unidades De Saúde

Nicoletti

Kubota

2017

Infarma

View full text Add to dashboard Cite

Patients with chronic diseases, especially hypertension and diabetes, need constant monitoring by health professionals, since the lack of control of both, blood glucose and blood pressure, are the precursors of fatal attacks on the kidney functions, cardiovascular problems on top of generating costs to the Public Health System. The main goal of the work is to seek evidence to corroborate the benefits of Pharmaceutical Care to patients with chronic non-communicable diseases, in particular, hypertension and diabetes. The research is a narrative review based on articles available in the scientific databases Web of Science, SciELO, Virtual Health Library, USP Bibliographic Database (DEDALUS) and PubMed-NCBI, as well as, on epidemiological data found in DATASUS as well as on Brazilian and international guidelines associated with hypertension and diabetes. The inclusion criteria established was to consider complete articles addressing the main goal of the research, from 2000 up to 2016, written in Portuguese, English or Spanish, presenting conclusive results. The exclusion criteria were satisfied by publications that did not meet the inclusion criteria. It was observed that the practice of pharmaceutical care had an impact on the adherence rate to treatment in hypertensive and/or diabetic patients, providing clinical improvement and increasing the quality of life, also generating socioeconomic benefits. It is important to emphasize that Pharmaceutical Care is not offered in isolation from other health services, but in collaboration with patients as well as with the multidisciplinary health team; by having each professional acting in their field of expertise benefits both, i.e., the patient and the public health system. Keywords: pharmaceutical care; hypertension; type 2 diabetes mellitus; treatment adherence. RESUMOPacientes portadores de doenças crônicas, em especial, hipertensão e diabetes, necessitam acompanhamento constante do profissional da saúde, pois o descontrole tanto da glicemia como da pressão arterial é precursora de crises fatais do funcionamento de rins, problemas cardiovasculares e motores, gerando custos evitáveis ao sistema público de saúde. O objetivo desse trabalho é buscar evidências que demonstrem os benefícios dos cuidados farmacêuticos a pacientes portadores de doenças crônicas não transmissíveis, em especial, hipertensão e diabetes tipo 2, por meio A pesquisa é uma revisão narrativa utilizando busca de artigos nas bases científicas de dados Web of Science, SciELO, Biblioteca Virtual em Saúde, Bancos de Dados Bibliográficos da USP (DEDALUS) e PubMed-NCBI, bem como dados epidemiológicos do DATASUS e diretrizes brasileiras, para a contextualização de hipertensão e diabetes. Foi observado que a prática de cuidados farmacêuticos impactou no índice de adesão ao tratamento em pacientes hipertensos e/ou diabéticos, proporcionando melhora clínica e na qualidade de vida gerando, ainda, um benefício socioeconômico. É importante enfatizar que o cuidado farmacêutico não é praticado isoladamente de ...

show abstract

Effect of pharmacist intervention on glycemic control in diabetes

Cited by 81 publications

References 17 publications

Cardiovascular risk rate in hypertensive patients attended in primary health care units: the influence of pharmaceutical care

Cardiovascular risk rate in hypertensive patients attended in primary health care units: the influence of pharmaceutical care

Quality of life perception of type 1 diabetic patients treated with insulin analogs and receiving medication review with follow-up in a public health care service from Ponta Grossa-PR, Brazil

Benefícios Decorrentes De Prática Do Cuidado Farmacêutico Em Hipertensão E Diabetes Tipo 2 Para Sua Efetivação Em Unidades De Saúde

Contact Info

Product

Resources

About